Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThisCART19A in Adult Patients With B Cell Malignancies After Failure of Autologous CAR-T Therapy
NCT05640713Phase 1Unknown
- Sponsor
- Henan Cancer Hospital
- Start
- Dec 2022
- Primary completion
- Feb 2025
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of thiscart19a in acute lymphoblastic leukemia (ALL) and lymphoma, sponsored by Henan Cancer Hospital. Primary endpoints: Dose limited toxicity at 28 days, Objective Response Rate at 3 months and 1 more. Status: unknown.
02
Drugs
thiscart19a
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoma
Beyond the preview
Go deeper on NCT05640713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05640713.